GlassScriptPhysician profile
Hannah Zelnik
NPI 1932704293
$3,751.63
in general payments reported to CMS, 2019-2025
25 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $377 · 2022: $942 · 2023: $1,714 · 2024: $611 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,432.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $639.21 | 2022-2025 | |
| Janssen Biotech, INC. | $590.42 | 2021-2025 | Stelara, Tremfya |
| Celgene Corporation | $379.34 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $347.63 | 2021-2024 | Entyvio, Gattex |
| Pfizer INC. | $344.16 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $322.62 | 2021-2024 | Xifaxan, Trulance |
| Janssen Scientific Affairs, LLC | $149.17 | 2023 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $117.94 | 2021 | |
| Phathom Pharmaceuticals, INC. | $97.83 | 2024 | Voquezna |
| Ardelyx, INC. | $97.56 | 2022-2023 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $91.81 | 2022-2023 | Dupixent |
| Renovia INC | $86.81 | 2021 | |
| Genzyme Corporation | $79.09 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $69.04 | 2023 | |
| Ironwood Pharmaceuticals, INC | $52.15 | 2023-2024 | Linzess |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $51.06 | 2023 | Idacio |
| Lilly USA, LLC | $49.44 | 2023 | |
| Qol Medical, LLC | $34.20 | 2023 | Sucraid |
| Amgen INC. | $32.25 | 2022 | |
| Intercept Pharmaceuticals, INC. | $24.45 | 2023 | Ocaliva |
| Daiichi Sankyo INC. | $22.50 | 2023 | Injectafer |
| Pacira Pharmaceuticals Incorporated | $22.26 | 2023 | Exparel |
| Ferring Pharmaceuticals INC. | $20.45 | 2022 | |
| Endogastric Solutions, INC | $15.15 | 2024 | Esophyx |
| Merck Sharp & Dohme LLC | $15.09 | 2024 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Zelnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.